Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
McKesson
Moodys
Harvard Business School
Farmers Insurance
Colorcon
Dow
McKinsey

Generated: June 22, 2018

DrugPatentWatch Database Preview

Osi Pharms Company Profile

« Back to Dashboard

Summary for Osi Pharms
International Patents:119
US Patents:4
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Osi Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-002 Nov 18, 2004 RX Yes No 7,087,613*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-003 Nov 18, 2004 RX Yes Yes 6,900,221*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-002 Nov 18, 2004 RX Yes No 5,747,498*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-001 Nov 18, 2004 RX Yes No 7,087,613*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for OSI PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 25 mg, 100 mg and 150 mg ➤ Subscribe 2008-11-18

Supplementary Protection Certificates for Osi Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006 Austria ➤ Try a Free Trial PRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321
C/GB06/008 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919
0214 Netherlands ➤ Try a Free Trial 300214, 20150606, EXPIRES: 20200320
0817775/01 Switzerland ➤ Try a Free Trial FORMER REPRESENTATIVE: BOHEST AG, CH
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Farmers Insurance
Fuji
Boehringer Ingelheim
UBS
Julphar
QuintilesIMS
Covington
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.